Accordingly, it is recommended that cisplatin-based adjuvant chemotherapy in patients with completely resected stage I–IIIA NSCLC be carefully applied after examining the expression levels of β-catenin and NME1. This evidence concerns the gene NME1 and non-small cell lung carcinoma.